10x Genomics (TXG) AI Stock Analysis

• Market Cap: $2.32B
• Dividend Yield: N/A
• Average Volume (3M): 2.98M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.46
• Revenue Growth: 1.92%
• EPS Growth: 59.18%
• Country: US
• Employees: 1,306
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.22
• Shares Outstanding: 116,474,180
• 10 Day Avg. Volume: 3,697,052
• 30 Day Avg. Volume: 2,982,686
• PEG Ratio: 0.31
• Price to Book (P/B): 2.44
• Price to Sales (P/S): 2.83
• P/FCF Ratio: -301.92
• Enterprise Value/Market Cap: 0.46
• Enterprise Value/Revenue: 1.67
• Enterprise Value/Gross Profit: 2.43
• Enterprise Value/Ebitda: -34.80
• 1Y Price Target: $16.25
• Price Target Upside: -11.40% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): -0.52
• Revenue Forecast (FY): $633.04M

• Rating: 60 Neutral
• Price Target: $18.00 ▼(-1.85% Downside)

10x Genomics' stock score is primarily driven by strong technical momentum, despite weak financial performance and valuation metrics. The company's effective cash management and strong gross margins are positive, but ongoing profitability challenges and a negative P/E ratio weigh heavily. The earnings call highlights mixed results, with some growth in consumables but overall revenue declines.

Positive Factors

Strong Cash Position

A robust cash position enhances financial flexibility, allowing the company to invest in growth opportunities and weather economic uncertainties.

Product Innovation

Continuous product innovation strengthens competitive positioning and can drive future revenue growth by meeting evolving customer needs.

Partnership with Anthropic

Strategic partnerships can enhance product offerings and market reach, potentially leading to increased adoption and customer satisfaction.

Negative Factors

Decline in Overall Revenue

A decline in overall revenue indicates potential challenges in maintaining market share and pricing power, affecting long-term growth prospects.

Challenges in U.S. Market

Challenges in key markets like the U.S. can hinder revenue growth and reflect broader issues in customer demand and funding availability.

Decline in Instrument Revenue

Significant declines in instrument revenue suggest potential issues with product demand or market saturation, impacting future sales growth.

10x Genomics Business Overview & Revenue Model

Company Description

10x Genomics (TXG) is a biotechnology company that specializes in genomic sequencing and analysis technologies. Founded in 2012 and headquartered in Pleasanton, California, the company operates primarily in the life sciences sector, providing advanced solutions for single-cell analysis, spatial genomics, and immune profiling. 10x Genomics' core products include their Chromium platform and associated reagents, which enable researchers to conduct high-throughput genomic studies across various applications, including cancer research, immunology, and drug discovery.

How the Company Makes Money

10x Genomics generates revenue primarily through the sale of its genomic analysis systems, consumables, and software. The company offers a range of products, including the Chromium Controller, Chromium Chips, and associated reagents, which represent a significant portion of its revenue. Additionally, 10x Genomics provides software tools and cloud-based solutions that facilitate data analysis and interpretation for researchers. The company benefits from ongoing partnerships with academic institutions, research organizations, and pharmaceutical companies, which often lead to bulk purchases of its products for large-scale genomic studies. Furthermore, the expanding applications of its technology in areas such as personalized medicine and drug development contribute to its growing customer base and revenue potential.

10x Genomics Financial Statement Overview

Summary

10x Genomics demonstrates strong gross margins and effective cash management, but faces challenges with profitability and revenue growth. The balance sheet is stable with low leverage, yet the company struggles to generate positive returns on equity. Continued focus on improving operational efficiency and revenue growth is essential for future financial health.

Income Statement

10x Genomics has shown a decline in revenue growth with a negative growth rate of -41.2% in the TTM period. The company maintains a relatively high gross profit margin of 68.8%, indicating strong cost management. However, the net profit margin is negative at -11.9%, reflecting ongoing losses. The EBIT and EBITDA margins are also negative, suggesting challenges in achieving operational profitability.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.11, indicating conservative leverage. However, the return on equity is negative at -10.3%, reflecting challenges in generating returns for shareholders. The equity ratio is not explicitly calculated, but the balance sheet shows a strong equity base relative to total assets.

Cash Flow

10x Genomics has improved its free cash flow, with a growth rate of 43.56% in the TTM period. The operating cash flow to net income ratio is 0.60, indicating some ability to convert earnings into cash. The free cash flow to net income ratio is high at 0.92, suggesting effective cash management despite net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	641.81M	610.78M	618.73M	516.41M	490.49M	298.85M
Gross Profit	441.79M	414.48M	409.31M	396.02M	416.40M	240.38M
EBITDA	-30.81M	-133.99M	-205.11M	-128.49M	-24.59M	-513.77M
Net Income	-76.32M	-182.63M	-255.10M	-166.00M	-58.22M	-542.73M
Balance Sheet
Total Assets	1.03B	918.64M	965.14M	1.03B	1.02B	929.34M
Cash, Cash Equivalents and Short-Term Investments	482.08M	393.40M	388.69M	429.98M	587.45M	663.60M
Total Debt	86.98M	82.61M	95.37M	95.18M	81.98M	62.98M
Total Liabilities	241.03M	208.50M	224.10M	223.24M	201.26M	190.27M
Stockholders Equity	785.12M	710.13M	741.04M	805.74M	817.57M	739.07M
Cash Flow
Free Cash Flow	81.65M	-5.73M	-64.72M	-165.27M	-122.65M	-256.29M
Operating Cash Flow	88.53M	6.66M	-15.20M	-33.61M	-21.37M	-217.90M
Investing Cash Flow	-63.23M	-32.63M	133.49M	-350.89M	-106.73M	-38.39M
Financing Cash Flow	9.08M	10.91M	13.67M	15.82M	35.30M	468.91M

10x Genomics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 18.34
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TXG, the sentiment is Positive. The current price of 18.34 is above the 20-day moving average (MA) of 14.95, above the 50-day MA of 13.41, and above the 200-day MA of 11.56, indicating a bullish trend. The MACD of 1.06 indicates Negative momentum. The RSI at 72.07 is Negative, neither overbought nor oversold. The STOCH value of 64.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TXG.

10x Genomics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OMCL	69 Neutral	$1.62B	84.43	1.62%	―	10.67%	―
HNGE	64 Neutral	$3.59B	―	―	―	50.67%	-578.00%
WGS	61 Neutral	$4.24B	2,430.35	0.84%	―	50.50%	―
TXG	60 Neutral	$2.32B	―	-10.12%	―	1.92%	59.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SOPH	48 Neutral	$316.27M	-4.26	-86.09%	―	13.66%	-2.65%
SDGR	44 Neutral	$1.21B	―	-45.67%	―	32.90%	1.85%

10x Genomics Corporate Events

10X Genomics Earnings Call: Mixed Results Amid Challenges

The recent earnings call from 10X Genomics painted a mixed picture for investors and stakeholders. While the company showcased strong performance in spatial consumables and successful new product launches, these positives were somewhat overshadowed by declines in overall revenue and instrument sales. The ongoing macroeconomic challenges and funding uncertainties continue to pose significant hurdles for the company’s growth trajectory.

10x Genomics Reports Q3 2025 Financial Results

10x Genomics is a life science technology company specializing in single cell and spatial biology, providing integrated research solutions to advance human health.

10X Genomics Balances Growth and Challenges in Earnings Call

The recent earnings call of 10X Genomics painted a picture of cautious optimism. The company reported strong performances in China and spatial consumables, a favorable settlement with Bruker, and strategic acquisitions. However, these positive aspects were tempered by challenges in capital expenditure spending, decreased revenue in key regions, and uncertainties in academic funding. The overall sentiment was balanced, reflecting both positive achievements and significant hurdles.